Many clinicians caring for vulvovaginal conditions encounter a familiar challenge: patients whose symptoms persist despite standard treatments. Whether the issue is chronic vulvar pain, recurrent infections, genitourinary syndrome of menopause (GSM), or persistent tissue irritation, commercially available therapies do not always address the complexity of the vaginal environment.
One reason therapies may not fully address patient needs is that most treatments focus on active ingredients, while overlooking something equally important: the formulation base itself.
In vaginal medicine, the base of a topical therapy directly interacts with delicate mucosal tissue and the vaginal microbiome. Properties such as pH and osmolarity can influence epithelial integrity, tissue hydration, and microbial balance. When formulations are not aligned with the physiology of the vaginal environment, they may relieve symptoms temporarily while inadvertently contributing to irritation or microbiome disruption. Clinicians also report that many patients experience irritation with traditional formulation bases, leading providers to search for alternatives that are better tolerated by vulvovaginal tissue.
Historically, both commercially available FDA-approved products and traditional compounding bases were developed primarily to deliver active pharmaceutical ingredients rather than to support the vaginal microbiome or mucosal environment itself. As a result, many commonly used manufactured or compounded formulation bases have neutral pH or hyperosmolar characteristics that differ from the natural vaginal ecosystem and may stress epithelial cells or disrupt the Lactobacillus-dominant environment that supports vaginal health.
As our understanding of the vaginal microbiome and mucosal physiology evolves, formulation science is also beginning to advance toward bases designed specifically for this environment.
The vaginal environment functions best under specific physiological conditions, including:
• Low pH (approximately 3.8–4.5)
• Iso-osmolar environments that protect epithelial cells from dehydration
• Support for Lactobacillus dominance, which helps maintain microbial balance and pathogen resistance
When topical treatments respect these biological parameters, they are more likely to support tissue healing and microbial stability.
To address these challenges, BiomeNourish™ was developed as a compounded formulation base designed specifically for vaginal tissue. BiomeNourish™ is formulated with Bio-Match® technology to more closely match the natural vaginal environment by providing iso-osmolarity, physiologic acidic pH, and a hydration matrix designed to support mucosal comfort and barrier integrity. By aligning the formulation environment with vaginal physiology, BiomeNourish™ allows active ingredients to work within a microbiome-supportive context rather than against it.
Equally important is the pharmacopeia of topical ingredients that can be incorporated into these compounded formulations. Our network has curated a focused set of therapies commonly used in vulvovaginal medicine to address key drivers of symptoms, including vulvar pain, tissue inflammation, microbial imbalance, and epithelial fragility. These agents can be prescribed individually or in combination depending on the patient’s presentation, allowing clinicians to move beyond single-ingredient treatments and address multiple contributing factors simultaneously.
Compounded therapies are not intended to replace standard medications. Instead, they expand the clinician’s toolkit, offering additional options when commercially available products fall short or when patients require more individualized care.
Later this year, Clinical Care by Good Clean Love will introduce a clinician support platform designed to make microbiome-informed compounded therapies more accessible within the IVH provider network. This initiative will combine vaginal microbiome insights with thoughtfully designed compounded formulations, including the BiomeNourish base, giving clinicians additional tools to support patients with complex vulvovaginal symptoms.
More information about this program will be shared with the network as it becomes available.
Vaginal Biome Science (VBS), the Institute's sister company, is a pioneering biotechnology leader dedicated to revolutionizing women's vaginal healthcare through scientific innovation.
Interviews
Redefining Postpartum: Pelvic Floor Therapy for Birth Prep and Recovery
In this interview, Melanie Llanes, PT, DPT, redefines postpartum recovery by using pelvic floor physical therapy to support women through birth prep and healing well beyond the six-week check. She shares how education, prevention, and personalized care empower women to feel strong, informed, and confident at every stage of motherhood.
Vaginal conditions
Why “Just Water” Isn’t Enough: New Insights on Vulvar Hygiene
A 2025 review in Healthcare challenges the long-standing assumption that washing the vulva with plain water is the gentlest method. The authors present dermatologic and gynecologic evidence showing that water alone may disrupt the vulvar barrier, while mild, pH-balanced cleansers can better support hydration, comfort, and microbiota balance.
Interviews
Understanding Post-Cancer Challenges with Gina Franco, MSN, ANP-C
Gina Franco, MSN, ANP-C, discusses the often-overlooked sexual and vaginal health struggles cancer survivors face after treatment. She highlights how cancer therapy can disrupt vaginal tissues and how providers can better support whole-person healing through integrative care and patient-centered communication.
